Summary
Aduro BioTech Inc (Aduro BioTech) is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sting pathway activators; and B-select monoclonal antibodies to create immunotherapies for the treatment of cancers, infectious and autoimmune diseases. Its products under development are intended for the treatment of multiple indications, including pancreatic, lung, ovarian, prostate cancers, mesothelioma and glioblastoma. The company collaborates with various pharmaceutical companies to expand its products and technology platforms. Aduro BioTech is headquartered in Berkeley, California, the US.
Aduro BioTech Inc (ADRO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aduro BioTech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Aduro BioTech Acquires GVAX Assets From BioSante Pharma 13
Venture Financing 15
Aduro BioTech Raises USD51.4 Million in Series D Venture Financing 15
Aduro BioTech Raises USD55 Million in Series C Financing 16
Aduro BioTech Raises US$7 Million In Venture Financing 17
Aduro BioTech Raises US$6.5 Million In Venture Financing 18
Aduro BioTech Secures US$0.5 Million In Venture Financing 18
Aduro BioTech Secures US$19.25 Million In Series B Financing 19
Partnerships 20
Aduro Biotech Expands Agreement with Merck 20
University of California, Berkeley Enters into Agreement with Aduro Biotech 21
Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 22
Aduro BioTech Enters Into Co-Development Agreement With Protein Potential And Sanaria To Develop Malaria Vaccines 23
Licensing Agreements 24
Aduro BioTech Enters into Licensing Agreement with Stanford University 24
Aduro BioTech Enters into Licensing Agreement with UCB 25
Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 26
Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 27
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 28
Aduro BioTech Enters into Licensing Agreement with University of California, Berkeley 29
Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 30
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 31
Aduro BioTech Enters into Licensing Agreement with Karagen Pharma 32
BioSante Pharma Enters Into Licensing Agreement With Aduro BioTech 33
Aduro BioTech Enters into Licensing Agreement with Johns Hopkins University 34
Equity Offering 35
Aduro Biotech to Raise up to USD100 Million in Public Offering of Shares 35
Aduro BioTech Raises USD25 Million in Private Placement Shares 36
Aduro BioTech Raises USD136.8 Million in IPO 37
Acquisition 39
Aduro Biotech to Acquire BioNovion 39
Consegna Group Completes Acquisition Of Aspen Medisys 40
Aduro BioTech Inc - Key Competitors 42
Key Employees 43
Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 45
Financial Announcements 45
May 02, 2017: Aduro Biotech Reports First Quarter 2017 Financial Results 45
Mar 01, 2017: Aduro Biotech Announces Fourth Quarter and Full Year 2016 Financial Results 46
Nov 02, 2016: Aduro Biotech Reports Third Quarter 2016 Financial Results 48
Aug 03, 2016: Aduro Biotech Reports Second Quarter 2016 Financial Results 49
May 02, 2016: Aduro Biotech Announces First Quarter 2016 Financial Results 50
Mar 08, 2016: Aduro Biotech Announces Fourth Quarter and Full Year 2015 Financial Results 51
Corporate Communications 52
Apr 20, 2017: Aduro Biotech Announces Management Promotions 52
Sep 06, 2016: Aduro Biotech Appoints Oncology Expert and Industry Veteran Natalie Sacks, M.D. as Chief Medical Officer 53
Product News 54
Mar 24, 2016: Aduro Biotech Announces First Patient Dosed in Combination Clinical Trial of CRS-207 and Epacadostat to Treat Ovarian Cancer 54
Mar 06, 2017: Aduro Biotech Presents Data On BION-1301 at the 2017 American Association for Cancer Research Annual Meeting 55
Mar 06, 2017: Aduro Biotech Presents Data on Vaccine Technology targeting STING at the 2017 American Association for Cancer Research Annual Meeting 56
Product Approvals 57
Nov 21, 2016: Partial Clinical Hold Lifted and Enrollment Resumes for Aduro Biotech LADD Clinical Trials 57
Clinical Trials 58
May 26, 2017: Aduro Biotech to Host and Webcast an Investor Event in Conjunction with the 2017 ASCO Annual Meeting 58
Dec 03, 2016: Aduro Biotech Presents Preclinical Data Supporting Clinical Development of its Anti-APRIL Antibody, BION-1301, for the Treatment of Multiple Myeloma 59
Nov 12, 2016: Aduro Biotech Highlights Positive Clinical Results from Second Cohort of Phase 1b Mesothelioma Clinical Trial 60
Nov 07, 2016: Aduro Biotech Presents Preclinical Data Demonstrating Acute and Systemic Immune Activation through STING Pathway Stimulation with ADU-S100 62
Sep 27, 2016: Aduro Biotech Presents Encouraging Preclinical Data Showing on listeria-based immunotherapy construct 63
Sep 27, 2016: Aduro Biotech Presents Encouraging Preclinical Data Showing on Stimulator of Interferon Genes 64
Jun 04, 2016: Aduro Biotech Presents Encouraging Anti-Tumor Response Data From Ongoing Phase 1b Study in Malignant Pleural Mesothelioma at ASCO 65
May 16, 2016: Aduro Biotech Announces Phase 2b ECLIPSE Trial Misses Primary Endpoint in Heavily Pretreated Metastatic Pancreatic Cancer 66
May 12, 2016: Aduro Biotech Announces First Patient Dosed in Phase 1 Study of ADU-S100 for the Treatment of Cutaneously Accessible Tumors 67
Apr 28, 2016: Aduro Biotech Announces Key Preclinical Data Published Highlighting New Approach to Treat Multiple Myeloma 68
Apr 11, 2016: Aduro Biotech Chief Scientific Officer to Highlight the Potential of STING Activation in Cancer Immunotherapy in a Major Symposium at the 2016 American Association for Cancer Research Annual Meeting 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70
List of Tables
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aduro BioTech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aduro BioTech Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aduro BioTech Acquires GVAX Assets From BioSante Pharma 13
Aduro BioTech Raises USD51.4 Million in Series D Venture Financing 15
Aduro BioTech Raises USD55 Million in Series C Financing 16
Aduro BioTech Raises US$7 Million In Venture Financing 17
Aduro BioTech Raises US$6.5 Million In Venture Financing 18
Aduro BioTech Secures US$0.5 Million In Venture Financing 18
Aduro BioTech Secures US$19.25 Million In Series B Financing 19
Aduro Biotech Expands Agreement with Merck 20
University of California, Berkeley Enters into Agreement with Aduro Biotech 21
Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 22
Aduro BioTech Enters Into Co-Development Agreement With Protein Potential And Sanaria To Develop Malaria Vaccines 23
Aduro BioTech Enters into Licensing Agreement with Stanford University 24
Aduro BioTech Enters into Licensing Agreement with UCB 25
Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 26
Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 27
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 28
Aduro BioTech Enters into Licensing Agreement with University of California, Berkeley 29
Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 30
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 31
Aduro BioTech Enters into Licensing Agreement with Karagen Pharma 32
BioSante Pharma Enters Into Licensing Agreement With Aduro BioTech 33
Aduro BioTech Enters into Licensing Agreement with Johns Hopkins University 34
Aduro Biotech to Raise up to USD100 Million in Public Offering of Shares 35
Aduro BioTech Raises USD25 Million in Private Placement Shares 36
Aduro BioTech Raises USD136.8 Million in IPO 37
Aduro Biotech to Acquire BioNovion 39
Consegna Group Completes Acquisition Of Aspen Medisys 40
Aduro BioTech Inc, Key Competitors 42
Aduro BioTech Inc, Key Employees 43
Aduro BioTech Inc, Other Locations 44
Aduro BioTech Inc, Subsidiaries 44
List of Figures
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
